Business Wire Feed

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20th, 2026|

CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AMPLIFY Phase III trialWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination more...

Glen Cove Hospital Earns Presidential Quality Award

February 19th, 2026|

First New York hospital to receive Malcolm Baldrige National Quality Award for performance excellence in health careGLEN COVE, N.Y.--(BUSINESS WIRE)--Northwell’s Glen Cove Hospital has earned the Malcolm Baldrige National Quality Award, which recognizes performance excellence more...

Veracyte to Participate in Upcoming Investor Conferences

February 19th, 2026|

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on more...

Decorated Senior Army Officer Tal Sullivan Joins Battelle

February 19th, 2026|

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle announced today that Tal Sullivan, a highly decorated retired U.S. Army Special Forces (Green Beret) Colonel with more than 30 years of military and leadership experience, has joined the organization as Senior more...

Concord Technologies Celebrates 30 Years of Innovation and Leadership

February 19th, 2026|

Company empowers healthcare organizations by creating a smarter, faster, and more connected information ecosystem, achieving true interoperability and enhancing care deliverySEATTLE--(BUSINESS WIRE)--Concord Technologies, a leading provider of Secure Document Exchange, Intelligent Document Processing, and Interoperability more...

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

February 19th, 2026|

Designations provide market exclusivity as well as other development incentivesBOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.